New cancer clinical trial: Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast Cancer

Published on: July 31, 2018 at 12:00PM
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Triple-Negative Breast Carcinoma;   Progesterone Receptor Negative;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Drug: Carboplatin;   Biological: Durvalumab;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel;   Biological: Personalized Synthetic Long Peptide Vaccine;   Drug: Poly ICLC
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2mZFCAT